Choose Your Country or Region

PD98059

Name: PD98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (435 reviews)

Catalog No.S1177

For research use only.

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

CAS No. 167869-21-8

Selleck's PD98059 has been cited by 435 publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Related Compound Libraries

Other MEK Products

Cobimetinib (GDC-0973)^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Download Inhibitor Catalog

MEK Signaling Pathway Map

Biological Activity

Description

Features

Does not inhibit c-Raf phosphorylated MEK1.

Targets

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

A2780	Ml\iSpVv[3Srb36gRZN{[Xl?	M{DCUlIxyqEQvF2=	MlPoNUBp		MXzicI9kc3NiRGTDSE1qdmS3Y3XkJGRTPSCneIDy[ZN{cW:w	NGTZWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5Olg3Oid-MkO2PVY5PjJ:L3G+
AML 1#	M3ruT2Fxd3C2b4Ppd{BCe3OjeR?=	M2r2NlIxyqEQvF2=	NGLuZ\|YyOiCq		M{[wdIVvcGGwY3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgV\|E>	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5ME[2PVEoRjJ\|N{C2OlkyRC:jPh?=
KG-1	NFrvOWFCeG:ydH;zbZMhSXO\|YYm=	NHH4TY4zOMLizszN	MlLLNVIhcA>?		Mmnp[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=>	NVTINIUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFY3QTFpPkKzO\|A3PjlzPD;hQi=>
HUVECs	NEfNZ3RCeG:ydH;zbZMhSXO\|YYm=	M4jjWVIwPCEQvF2=	MVKyOE81QCCq		MlrCbY5lfWOnczDj[YxtKGSnYYTo	M1PLVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3OVIxLz5{M{ewO\|UzODxxYU6=
HepG2	NEX4VGtHfW6ldHnvckBCe3OjeR?=	NWHLUHUyOjEEoN88US=>	MYqyOEBp		NXvKd3k1cW6qaXLpeJMhfGinIFjPMVEheHKxdHXpckBmgHC{ZYPzbY9vKGOxLYTy[YF1\WRid3n0bEBu\XSob4LtbY4>	NYPHPZB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc3ODlpPkKzO\|A4PjB7PD;hQi=>
NB4	M1Tj[WFxd3C2b4Ppd{BCe3OjeR?=	NGDv[JUyOC9{MD:2NEDPxE1?	NF7nOpAyNjViaB?=	NEnyfnFFVVOR	Ml7p[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2ZXSge4l1cCCSYXPsbZRigGWu	Mn;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5M{W1OFEoRjJ\|N{O1OVQyRC:jPh?=
BxPC-3 cells	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUmxPVZTOjEEoN88US=>	MnPPNE42KGh?		NXHXW2l2cW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC=	MlfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NkSwOFYoRjJ\|N{[0NFQ3RC:jPh?=
MKN45	NFvxNYlCeG:ydH;zbZMhSXO\|YYm=	Mn7nNVAh\|ryPwrC=	Mki3NlQhcA>?		MYHpcoNz\WG\|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?	NUewS2hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI2QDhpPkKzO\|kzPTh6PD;hQi=>
SGC7901	NGSyTnJCeG:ydH;zbZMhSXO\|YYm=	MWSxNEDPxE4EoB?=	M3u0XFI1KGh?		MWjpcoNz\WG\|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?	MmCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
MKN45	M4PKTWZ2dmO2aX;uJGF{e2G7	NXvONlV6OTBizszNxsA>	NIrQTWwzPCCq		M1uwbIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	NEPOVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M134OlExKM7:TdMg	NHLKeXAzPC92OD:3NkBp		NVPPWJRscW6qaXLpeJMh[2WubDDndo94fGhiY3:teJJm[XSnZDD3bZRpKESDUGS=	MnrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
MKN45	M4DM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSxNEDPxE4EoB?=	MYiyOE81QC95MjDo		M1vrT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	M{DoVGZ2dmO2aX;uJGF{e2G7	NWWy[mZ[OTBizszNxsA>	M3HVeVI1KGh?		NG\pUldqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:\|cHjvdplt[XSnZDDFVmsyNzJ?	NXXxXHhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI2QDhpPkKzO\|kzPTh6PD;hQi=>
HUASMCs	MmP6SpVv[3Srb36gRZN{[Xl?	MlzINVAh\|ryPwrC=	MXeyOEBp		MUfkbY1qdmm\|aHXzJGFv\yCLST3jZZV{\WRiU1;DV\|MhdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vyqB?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzNkS2PEc,OjN6MU[0Olg9N2F-
HUASMCs	NGDpRWhHfW6ldHnvckBCe3OjeR?=	MkjVNVAh\|ryPwrC=	NV32bmhXOjRiaB?=		NHXJ[GRqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs	NGL6bXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ixOlQ3QCd-MkO4NVY1Pjh:L3G+
EPOR/CR3	NVPpUVd1TnWwY4Tpc44hSXO\|YYm=	MWS1NOKh\|ryP	M3PlRlMhcA>?		NH7xNHpz\WS3Y3XzJGVRVyCjbnSvc5IhUUxvMz3pcoR2[2WmIITo[UB1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb39CpC=>	MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkC3N\|EoRjJ\|OEKwO\|MyRC:jPh?=
NB4	NGXFNJNHfW6ldHnvckBCe3OjeR?=	NG\SbYsyOCEQvF5CpC=>	NFvGZ\|Y4OiCq	NHfaeVBFVVOR	MWjpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w	NF;JU\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HL60	NVnmOGNnTnWwY4Tpc44hSXO\|YYm=	M3HY[FIxyqEQvF2=	NUPRZpM{PzJiaB?=	M2TSZmROW09?	M2PMZolvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36=	MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MkW1PFUoRjJ\|OEK1OVg2RC:jPh?=
HUVECs	NYrsNGdxTnWwY4Tpc44hSXO\|YYm=	MoXuNlUh\|ryP	M1r4R\|EhcA>?		NUjERVVjcW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36=	MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEGwNFgoRjJ\|OUCxNFA5RC:jPh?=
LNCaP	MlnSSpVv[3Srb36gRZN{[Xl?	MUCxNEDPxE4EoB?=	NGfjcmgyKGh?		NGH3TmFl\WO{ZXHz[ZMhfGinIFXHSkB2eHKnZ4XsZZRm\CCyLWnCMVE>	M1WxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEO4N\|E5Lz5{M{izPFMyQDxxYU6=
HL-60	NVjVbXU6SXCxcITvd4l{KEG\|c3H5	NIHpcHE2OMLizszN	NVLSV406OSCq		M3nSU5Jme2O3ZYOgRmEyPDVibXXkbYF1\WRiYYDvdJRwe2m\|	NETpRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0PFc2OSd-MkO5OFg4PTF:L3G+
HepG2	MV3GeY5kfGmxbjDBd5NigQ>?	MorUOFAh\|ryP	NGq1WJk3NzF{IHi=		NH7lOJVqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCSTB?=	M136dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUSyPFUyLz5{M{m0Nlg2OTxxYU6=
HPAF-II	NVO2RWU4TnWwY4Tpc44hSXO\|YYm=	MkTjNVAh\|ryPwrC=	NWD6PWNOPiCq		NVS1co5{cW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{exNEc,OjN7N{O3NVA9N2F-
BxPC-3	NXfieWUxTnWwY4Tpc44hSXO\|YYm=	NIPtXHQyOCEQvF5CpC=>	MYK2JIg>		NUKxeZVicW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{exNEc,OjN7N{O3NVA9N2F-
COLO205	MVvBdI9xfG:\|aYOgRZN{[Xl?	M1\NWFExNzJyL{SwJO69VQ>?	MoPaNlQhcA>?		MWDpcoR2[2W\|IFTORUBt[WSmZYKg[o9zdWG2aX;u	NHq3UYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxPVExQCd-MkSwNVkyODh:L3G+
G292	M{mwdGFxd3C2b4Ppd{BCe3OjeR?=	MVqzNOKh\|ryP	NGn0U4szKGh?		NGfoXmpz\XO2b4Lld{Bk[XC\|YXnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp	Mni5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUK5N\|AoRjJ2MEGyPVMxRC:jPh?=
SGC7901	NGO3PJNCeG:ydH;zbZMhSXO\|YYm=	M4TKU\|IxyqEQvF2=	MmT6NUBp		M2\qZYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?=	NWjzb3R6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNlc4PTBpPkK0NFI4PzVyPD;hQi=>
MGC803	NUjhRoFrSXCxcITvd4l{KEG\|c3H5	M3;pPFIxyqEQvF2=	MWKxJIg>		MoDDbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU	NImxe\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECyO\|c2OCd-MkSwNlc4PTB:L3G+
HPMC	M{PhbmFxd3C2b4Ppd{BCe3OjeR?=	M3:4XVExyqEQvF2=	Mo\jNlTDqGh?		MkjwdoV3\XK\|ZYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBJT1CGUx?=	M2j1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESyPFM5Lz5{NEC0Nlg{QDxxYU6=
HCT-8	NU\BXlNQSXCxcITvd4l{KEG\|c3H5	M4HlTlExyqEQvF2=	M2K5S\|I1yqCq		MXnk[YNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTC1MWZW	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUW4OlMoRjJ2MEm1PFY{RC:jPh?=
HPMC	M3KzO2Z2dmO2aX;uJGF{e2G7	MoLZNVDDqM7:TR?=	M1jqXFQ5KGh?		MkTFdoV3\XK\|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM>	NX;uTFJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFI5OzhpPkK0NFQzQDN6PD;hQi=>
A549	NWjoOoNiTnWwY4Tpc44hSXO\|YYm=	NEnEbHU2OMLizszN	NH;1T5gzKGh?		MmLYZoxw[2u\|IFXST{BxcG:\|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R	NHX5e4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2O\|czPyd-MkSwOlc4Ojd:L3G+
Caco-2	M1X4SGFxd3C2b4Ppd{BCe3OjeR?=	Mln4NVDDqM7:TR?=	M3i1c\|I1yqCq		Mknj[IVkemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgOU1HXQ>?	M1rPVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1PFY{Lz5{NEC5OVg3OzxxYU6=
AGS	M4XKWGZ2dmO2aX;uJGF{e2G7	NHPCWXAyOCEQvF5CpC=>	M4TWSFAvPSCq		NGnKOZJqdmirYnn0d{B1cGVidYDy[Yd2dGG2aX;uJI9nKHSqZTDJUE05KGenbnW=	M4DpZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUC2NVY3Lz5{NEGwOlE3PjxxYU6=
Ca9-22	NIjBbodHfW6ldHnvckBCe3OjeR?=	NVztdJl4OyEQvF2=	NHvvdlQyNzJiaB?=		M3Hk[5Jm\HWlZYOgTIJTNWmwZIXj[YQhSVSILUKgdIhwe3Cqb4L5cIF1cW:w	NY\vdGtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlY2OzJpPkK0NVI3PTN{PD;hQi=>
Ca9-22	M2H4WGZ2dmO2aX;uJGF{e2G7	MoLCN{DPxE1?	M2TjeVEhcA>?		NF7tUWpi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44>	NHH6eZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOlU{Oid-MkSxNlY2OzJ:L3G+
HAECs	NX:2cllpTnWwY4Tpc44hSXO\|YYm=	MlvxNVAh\|ryP	NFjpdpMyKGh?		NW\oRYM{yqCjdITlcpVifGW\|IGTOSk3PuS2\|dHnteYxifGWmIFnDRW0uOSCjbnSgWmNCVS1zIHX4dJJme3Orb36=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|NE[1O{c,OjRzM{S2OVc9N2F-
Caco-2	NF:yPIlHfW6ldHnvckBCe3OjeR?=	MVi1NOKh\|ryP	MoPTOFhp	NUS1T4l[TE2VTx?=	MYrlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD\|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW\|wrDjc{11emWjdHXkJJdqfGhiRHX4	M1fTbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[xOlk2Lz5{NEG2NVY6PTxxYU6=
MCF-7	NVnNWFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\BbFE6OTBizszN	M4jsRlQ5cA>?	Mk\QSG1UVw>?	MkXldoV3\XK\|ZYOgRm5HNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5Q>	NVO1OmdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlM1ODRpPkK0NVY{PDB2PD;hQi=>
SMMC7721	MWXGeY5kfGmxbjDBd5NigQ>?	MlLzNlUwPTBizszN	MVuyOEBp		M4TIPZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM\|LDqA>?	NV3kRmhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlgxPTZpPkK0NVY5ODV4PD;hQi=>
SGC7901	MWfBdI9xfG:\|aYOgRZN{[Xl?	MoXCOVDDqM7:TR?=	NVu5PY81OjRxNEivO\|IhcA>?	NV2yeG9lTE2VTx?=	NXfaN2p4cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDKRWszKHOqUl7B	M4fSOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe4NlQxLz5{NEG3PFI1ODxxYU6=
7721	NF3Ndm1CeG:ydH;zbZMhSXO\|YYm=	M1rtUVMxKM7:TR?=	M2DLXFUh\A>?		Mmm1[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	NHT6cFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVI2Oyd-MkSyNVEzPTN:L3G+
DLD-1	NH3T[WxHfW6ldHnvckBCe3OjeR?=	MYeyNOKh\|ryP	NYjFWIg3PDhiaB?=		M1znbJJm\HWlZYOgeIhmKEKQSWCzJIV5eHKnc4Ppc44heHKnLYTy[YF1\WRid3n0bEA2NWG8YT3kRy=>	M2j2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxOVgyLz5{NEKxNVU5OTxxYU6=
HT-29	M3HCcWZ2dmO2aX;uJGF{e2G7	NUO0bWF4OjEEoN88US=>	MkC0OFghcA>?		NYjqS3BNemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE	NITiNI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVU5OSd-MkSyNVE2QDF:L3G+
7402	NYnNeGVDSXCxcITvd4l{KEG\|c3H5	M{ThNVMxKM7:TR?=	NIKzfmc2KGR?		MUXk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	NYHZbZcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVEzPTNpPkK0NlEyOjV\|PD;hQi=>
MCF-7	M{DoV2Z2dmO2aX;uJGF{e2G7	NUnUd5hDOjBizszN	MmTHNUBp		MULhZo9tcXOqZYOg[ZhxemW\|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSn	NYD4W5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVYzQDlpPkK0NlE3Ojh7PD;hQi=>
MCF-7	NWXhVG5HSXCxcITvd4l{KEG\|c3H5	NUf4S3J5OjBizszN	MlW1NUBp		NX\qdVB1cW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk>	MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MU[yPFkoRjJ2MkG2Nlg6RC:jPh?=
CRL-2302	NUHBUHFnTnWwY4Tpc44hSXO\|YYm=	NIrjSJgzOCEQvF2=	NWXpVmtmOC53IHi=		M1LYfIlvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=>	NIDGVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyO\|kyQCd-MkSyNlc6OTh:L3G+
ARPE-19	Mn7WSpVv[3Srb36gRZN{[Xl?	NWHDeVFQOjBizszN	NEjG[XoxNjViaB?=		NYO4OYJocW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1	MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{Mke5NVgoRjJ2MkK3PVE5RC:jPh?=
MG-63	MlTxSpVv[3Srb36gRZN{[Xl?	NXXkdId1OjBizszN	MWKwMlUhcA>?		M4LubYJtd2OtczD0bIUhS0hvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBGVEtzIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ\|OU[0NEc,OjR{M{m2OFA9N2F-
SGC-7901	NG\QTmxCeG:ydH;zbZMhSXO\|YYm=	NEXzO5ozOCEQvF2=	M2flWFI1KGh?		NYXPUlRFcW6qaXLpeJMhS1BvbXXkbYF1\WRiYYDvdJRwe2m\|	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2MUO1NUc,OjR{NEGzOVE9N2F-
NUGC2	M1zJbWZ2dmO2aX;uJGF{e2G7	MVG1NEDPxE1?	NEG2fFM1QCCq	M4ToPGROW09?	NVTjbo5qcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NH3hNJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
NUGC3	M1j6SWZ2dmO2aX;uJGF{e2G7	M3[wVVUxKM7:TR?=	M2jsO\|Q5KGh?	MnPDSG1UVw>?	MYfpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
KATOIII	MlL4SpVv[3Srb36gRZN{[Xl?	MnTFOVAh\|ryP	MXS0PEBp	NEL1RZhFVVOR	MWPpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
NCI-N87	NUfodVRNTnWwY4Tpc44hSXO\|YYm=	MYq1NEDPxE1?	NHy3NZA1QCCq	MoPWSG1UVw>?	MknvbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	M3qyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
OE19	MXjGeY5kfGmxbjDBd5NigQ>?	MkjzOVAh\|ryP	NYK0dXJmPDhiaB?=	MXHEUXNQ	MVHpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
MKN7	MnXTSpVv[3Srb36gRZN{[Xl?	MlXIOVAh\|ryP	M2fRZVQ5KGh?	M1exOGROW09?	MmLSbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
TE4	MXnGeY5kfGmxbjDBd5NigQ>?	MUG1NEDPxE1?	MWS0PEBp	NFe0fI5FVVOR	Ml[weZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NFPqOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KYSE30	MVHGeY5kfGmxbjDBd5NigQ>?	MXm1NEDPxE1?	MV:0PEBp	M1PvNGROW09?	MUL1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	MofNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE5	MmXkSpVv[3Srb36gRZN{[Xl?	MUS1NEDPxE1?	NUOyZ2EyPDhiaB?=	MnvmSG1UVw>?	NGjmT3J2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	M1uzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS0NFI{Lz5{NEK0OFAzOzxxYU6=
TE1	MYDGeY5kfGmxbjDBd5NigQ>?	NF3hd482OCEQvF2=	NVTucndVPDhiaB?=	MkHxSG1UVw>?	NYfyR5Q1fXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	NWTvbphjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE3	MVvGeY5kfGmxbjDBd5NigQ>?	NH7ETGM2OCEQvF2=	M2Djc\|Q5KGh?	M3HnbGROW09?	NWTwfVFsfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
KYSE30	MX7GeY5kfGmxbjDBd5NigQ>?	MknwNlAwPTBxMUCwJO69VQ>?	M{DifVQ5KGh?	NX62bVh{TE2VTx?=	NIfTWm1qdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE1	NYeyWIZzTnWwY4Tpc44hSXO\|YYm=	MVKyNE82OC9zMECg{txO	NGnQT3g1QCCq	M4T5[GROW09?	M3T1UIlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NVPjZ29HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE4	NEX1cHZHfW6ldHnvckBCe3OjeR?=	M1qw[\|IxNzVyL{GwNEDPxE1?	MX:0PEBp	NFLJU3JFVVOR	NFvzdFVqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
HT29	MoTnSpVv[3Srb36gRZN{[Xl?	M3\5UlExKM7:TR?=	M2[4W\|IhcA>?		MWXpcohq[mm2czDv[kBLSUt{LDDFVmsyNzJiYX7kJHNVSVR\|IIDoc5NxcG:{eXzheIlwdg>?	NH7hUXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2OVI6Oyd-MkSyOlUzQTN:L3G+
HepG2	NHfrUW5CeG:ydH;zbZMhSXO\|YYm=	NFW5S2ozOCEQvF2=	MVmyOEBp		M4nXVIlvcGmkaYTzJGVTUzFxMjDwbI9{eGixconsZZRqd25iYX7kJIVvcGGwY3XzJHZDOS2rbnT1Z4VlKGGyb4D0c5Nqew>?	NF3B[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0O\|kxQSd-MkSyOFc6ODl:L3G+
HepG2	Mn7lSpVv[3Srb36gRZN{[Xl?	MYCyNEDPxE1?	MkK1NkBp		MmHY[Y5p[W6lZYOgWmIyNWmwZIXj[YQhTk:[T{PhJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eR?=	MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEe5NFkoRjJ2MkS3PVA6RC:jPh?=
MC-3	M2K5N2Fxd3C2b4Ppd{BCe3OjeR?=	M3XSTFExKM7:TR?=	MkntNlQhcA>?		MoLIdI91\W62aXH0[YQhVUWVQz3pcoR2[2WmIHHwc5B1d3OrczDpckAh[2WubIO=	NEDJZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3NFUzOyd-MkSyO\|A2OjN:L3G+
Raji	M1HkSWZ2dmO2aX;uJGF{e2G7	NUi3eHBKOTBizszN	MUCxJIg>		Mlm2Zoxw[2u\|IHjzRmFHTiCrbnT1Z4VlKEW{a{GvNkBxcG:\|cHjvdplt[XSrb36=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4OU[zNEc,OjR{Nkm2N\|A9N2F-
Raji	M4faWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjG[Xp6OTBizszN	M3jaOlEhcA>?		NGfue3FqdmirYnn0d{B1cGViYnHzZYwhd3JiaIPCRWZHNXO2aX31cIF1\WRiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJk>	M4Cx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[5OlMxLz5{NEK2PVY{ODxxYU6=
A549	NH62NXJHfW6ldHnvckBCe3OjeR?=	NXLldJIxOzBizszN	Mmm1NE42KGh?	NF\qVGRFVVOR	MoPvbY5pcWKrdIOgeIhzd22kaX6tbY5lfWOnZDDDM2VDWM7{IGTodlI{PcLicHjvd5Bpd3K7bHH0bY9v	MmTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{e2PVYoRjJ2Mke3Olk3RC:jPh?=
HCSMCs	NHX6N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D6NVExKM7:TR?=	MknzNlQhcA>?		M1q4ToJtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w	NUnKOY9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVI{QDFpPkK0N\|EzOzhzPD;hQi=>
PANC-1	MX7GeY5kfGmxbjDBd5NigQ>?	MYmyNEDPxE1?	NFXvPZM1QCCq		M1zJV4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJO6VPkRiaX6gdoV{eG:wc3WgeI8hfGinIGDQRXLPvMLiYXfvcol{fMLi	MlrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUSxN\|MoRjJ2Mkm0NVM{RC:jPh?=
A549	NF3ESFhHfW6ldHnvckBCe3OjeR?=	MVuzNEDPxE1?	M33z[FAvPSCq	NVe1Not[TE2VTx?=	NFLUd4FqdmirYnn0d{B1cGVidHjyc41jcW5vaX7keYNm\CCLTD24M2NZS0x6LVz1Z{Bi[3Srdnn0fS=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{[5Okc,OjR{N{e2PVY9N2F-
SW480	NVTaS5oxTnWwY4Tpc44hSXO\|YYm=	M{TYblExKM7:TR?=	NUjsZZFZOjBiaB?=	Ml7sSG1UVw>?	M335V5N2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=>	NW\tSpZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQ{PjZpPkK0N\|I1OzZ4PD;hQi=>
HEK 293	NITwS3FHfW6ldHnvckBCe3OjeR?=	M3zqRlExKM7:TR?=	M{XqUFUhcA>?	NEewUG9FVVOR	NF34bYxqdmirYnn0d{BYdnRvaX7keYNm\CEQsj3jZZRmdmmwL2TDSlQh[WO2aY\peJkh[W6mIH71Z4xm[XJizsKtZ4F1\W6rbjDhZ4N2dXWuYYTpc44>	M4nPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0N\|Y3Lz5{NEOyOFM3PjxxYU6=
HEK 293	NX\mV2VOTnWwY4Tpc44hSXO\|YYm=	NWGxWGt[OTBizszN	NGTC[Wg2KGh?	Mk\ySG1UVw>?	NH3GSm9{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk>	M{jlflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0N\|Y3Lz5{NEOyOFM3PjxxYU6=
HL-60	NV75RlFzTnWwY4Tpc44hSXO\|YYm=	MoH3NVAwOjBizszN	NV;jOXF6OSCq		MVnpcohq[mm2czD0bIXDqE5wIHPobY5mdnOrc3X4eJJi[3UEoHnu[JVk\WRiZHnm[oVz\W62aXH0bY9vKGmwdH:g[5JidnWub3P5eIV{	NYfXfm1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVcxOjBpPkK0N\|U4ODJyPD;hQi=>
HL-60	MX\GeY5kfGmxbjDBd5NigQ>?	NFLu[\|kzKML3TR?=	M{ewN\|E3KGh?	MnHlSG1UVw>?	NWGxUW5icW6qaXLpeJMhfGinIHHzd49kcWG2aX;uJI9nKHCVNkKxJHJi\i1zIHHu[EBPTkGWY{OsJIFv\CC2aHWgVmEucW6mdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YhdnWlbHXhdkBPTkGWY{O=	NXnKUIlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|AxPjhpPkK0N\|MxODZ6PD;hQi=>
HeLa	MXvGeY5kfGmxbjDBd5NigQ>?	NVq5UVNGPTBizszN	NYnSUZlROC53IHi=		NWP4WZpD[myxY3vzJHRTYC1zIH71Z4xm[XJibXnndoF1cW:wIHHu[EBVYE6LUDDkc5dvNXKnZ4XsZZRqd25?	NFPFb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3OlgzPyd-MkSzO\|Y5Ojd:L3G+
HUVECs	MV7GeY5kfGmxbjDBd5NigQ>?	MYCxNOKh\|ryP	MVmxJIg>		NEnqW4NqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG\|ZR?=	NILMN4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4OVExQSd-MkSzPFUyODl:L3G+
MCF-7	NXjk[ZlCTnWwY4Tpc44hSXO\|YYm=	MUGxNOKh\|ryP	NInjPWEyOC9\|MDDtbY4>		MXXy[YR2[2W\|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:\|cHjvdplt[XSrb36=	NVK4NmJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVA5OTlpPkK0N\|kxQDF7PD;hQi=>
HGC-27	M4HQVWFxd3C2b4Ppd{BCe3OjeR?=	NFjL[ZYyKML3TR?=	M3XQflEhcA>?		NUnHTHpQe3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:\|cx?=	NFvaUVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxOlM1QSd-MkS0NVY{PDl:L3G+
PC3	NYLBTJJzSXCxcITvd4l{KEG\|c3H5	MUG1NEDPxE1?	MWiwMlUhcA>?		Mn2wbY5pcWKrdIOgUWh[NTR2OT3pcoR2[2WmIHHwc5B1d3Orc9Mg	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{NEi4PUc,OjR2MkS4PFk9N2F-
HPAEpiCs	M1zmNmZ2dmO2aX;uJGF{e2G7	MUKzNEDPxE1?	MVWxJIg>		MVLpcohq[mm2czDUUmYu\|rFic4TpcZVt[XSnZDDwOFIweDR2IF3BVGsheGixc4Doc5J6dGG2aX;u	NFrQTpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0NVg4OCd-MkS0OFE5PzB:L3G+
BeWo	MmHZSpVv[3Srb36gRZN{[Xl?	NVTwRVFqOTEEoN88US=>	Ml;qNkBp		MofZbY5pcWKrdIOgSXJMOS9{	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{O4OFYoRjJ2NEOzPFQ3RC:jPh?=
A498	NFnldHhCeG:ydH;zbZMhSXO\|YYm=	MVS1NOKh\|ryP	M1fsZ\|I1KGh?		MUPwc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?=	MnO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEi0O\|YoRjJ2NUC4OFc3RC:jPh?=
NHBE	M{jmfmZ2dmO2aX;uJGF{e2G7	NE\4c3AzNzJyIN88US=>	MlKwNkBp		NWHqVmtC[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OUWyOkc,OjR2N{m1NlY9N2F-
A375	NXLXZYFrS2WubDDJcpZie2mxbjDBd5NigQ>?	MnrMNVDjiJN{MDFCuW0>	MU[yOEBp		NHyxXWZz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?	NGL1TWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2OlA{Pid-MkS0OlYxOzZ:L3G+
HBMEC	M33SVmZ2dmO2aX;uJGF{e2G7	MlXrNVAh\|ryP	M{fJclEhcA>?		Mln5Zoxw[2u\|IG\FS2YucW6mdXPl[EBGeGiDMjDlfJBz\XO\|aX;u	MmnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NUi5PFIoRjJ2NEW4PVgzRC:jPh?=
HCT-15	M4\3fGZ2dmO2aX;uJGF{e2G7		NGPyZ5oyKGh?		MVHheJRmdnWjdHXzJHBITTJvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiRYLrxsA>	M2H5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOxOFI2Lz5{NUSzNVQzPTxxYU6=
HCT-15	MkPaRZBweHSxc3nzJGF{e2G7		M2m0UVEhcA>?		MUnhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{	NIXPN2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzNVQzPSd-MkW0N\|E1OjV:L3G+
786-O	MUnBdI9xfG:\|aYOgRZN{[Xl?	Ml2zOVDDqM7:TR?=	NWDjeotLOjRiaB?=		M{PtPZBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D	Ml3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEi0O\|YoRjJ2NUC4OFc3RC:jPh?=
HepG2	NHfwN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSyNEDPxE1?	NHXwVJEzPCCq		M4LXVZN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBidmRiaX72ZZNqd25?	MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkC0PFgoRjJ3NU[wOFg5RC:jPh?=
SW480	M{T5bWZ2dmO2aX;uJGF{e2G7	M3q3cVIxyqEQvF2=	M3HiSFHDqGh?		NWfEdJN{emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBCXEZ\|IIDyc5RmcW5?	NWrpW\|lIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFc5OTZpPkK1OFQ4QDF4PD;hQi=>
MDA-MB-231	NWnBOlhITnWwY4Tpc44hSXO\|YYm=	NW\Pd4trOjVizszN	MXWyMVMhcA>?		MnTl[IVkemWjc3XzJJAuTVKNMT:yJIFv\CCVMUCwRVQh\XiycnXzd4lwdg>?	NH7LNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OVg4PSd-MkW1OVU5PzV:L3G+
HepG2	NEnqVHBHfW6ldHnvckBCe3OjeR?=	MnS2NVAh\|ryP	NHLwdHY2KGh?		NFzVXJBjdG:la4OgdIhwe3Cqb4L5cIF1\WRiTVHQT5MhcW6mdXPl[EBjgSCneH;n[Y5wfXNiVFfGMe6zOQ>?	M3HL[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[wOFg5Lz5{NUW2NFQ5QDxxYU6=
MCF-7	MnK5SpVv[3Srb36gRZN{[Xl?	M2PYN\|ExKM7:TR?=	NI\SPW8yKGh?		NEjVWFlqdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>?	M2LhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3NFEyLz5{NUeyO\|AyOTxxYU6=
H1355	MXXGeY5kfGmxbjDBd5NigQ>?	Mlz3NlUh\|ryP	MoPhNUBp		NX\NSFdD[my3boTzJJRp\SCEW3HdVE1qdmS3Y3XkJIlv[3KnYYPlJIlvKHCqb4PwbI8uS2itMTDhcoQheGixc4Doc{1GWktiZYjwdoV{e2mxbh?=	M3nGeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5NVgyLz5{NUe2PVE5OTxxYU6=
PC12	NVmxeZVXTnWwY4Tpc44h[XO\|YYm=				NHm1cINKdmirYnn0bY9vKG:oIH7ldpZmKGe{b4f0bEBn[WO2b4KtcYVlcWG2ZXSgUWFRKGurbnHz[UBi[3Srdnn0fUBqdiCqdX3hckBRSzF{IHPlcIx{NCCLQ{WwJF0hOiEQvF2u	NFzpfpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|M3Oyd-MUiwO\|c{PjN:L3G+
HT-29	NVy0XIdySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmjPOUBl[Xm\|		NIfafHhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDXV3QyKGG\|c3H5MEBKSzVyIE2gOEDPxE1w	NH7WPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3PFMyPid-MkWwO\|g{OTZ:L3G+
IEC6	M4nXWGZ2dmO2aX;uJIF{e2G7		NES2eZc2KG2rboO=		Mn[yTY5pcWKrdHnvckBw\iCPRVuxM\|IhcW5icnH0JGlGSzZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUzFxMjDsc49xKHCqb4PwbI9zgWyjdHnvckBld3OnZDCzNEBucW6\|IHLl[o9z\SC2bzDzeIlufWyjdHnvckB4cXSqIEGwKUB{\XK3bTDmc5IhPSCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZDygTWM2OCB;IESuNkDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB5OEOxOkc,OjVyN{izNVY9N2F-
NG 108-15	MlP0SpVv[3Srb36gZZN{[Xl?				NFTzSlREd26lZX70doF1cW:wIILldZVqemWmIITvJIFjd2yrc3igUWFRUyCjY4Tpeol1gSCrbjDtc5V{\SCwZYXyc4Jt[XO2b33hJIFv\CC{YYSg[4xqd22jIHj5ZpJq\CCQRzCxNFguOTViY3XscJMtKEGldHn2bZR6KD1iMUCg{txONg>?	NET5e4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUWzO\|M2PCd-MUW1N\|c{PTR:L3G+
PC12	NWrHfG1DTnWwY4Tpc44h[XO\|YYm=	M1PLUFExKHWP	MnjGOUBpenN?		MkPvRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKGG2IEGwJJVOKGGodHXyJFUhcHK\|IIDy[ZRz\WG2ZXSge4l1cCCMTlugbY5pcWKrdH;yJHNRPjByMUK1JIZweiBzIHjyJIJm\m:{ZTDjc41xd3WwZDDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2NU[4OUc,OjF\|NEW2PFU9N2F-
PC12	NF;4e4hHfW6ldHnvckBie3OjeR?=	M3rReFExKHWP	NIrsV4c2KGi{cx?=		NEnGV3BC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHnuJJJifCCSQ{GyJINmdGy\|IHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25iYYSgNVAhfU1iYX\0[ZIhPSCqcoOgdJJmfHKnYYTl[EB4cXSqIF3FT\|IhcW6qaXLpeI9zKFVyMUK2JIZweiBzIHjyJIJm\m:{ZTDjc41xd3WwZDDh[IRqfGmxbjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NGP2eHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
PC12	NVfwXWJYTnWwY4Tpc44h[XO\|YYm=	M3zk[\|ExKHWP	NG\KZVg2KGi{cx?=		NGnQUIhC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHnuJJJifCCSQ{GyJINmdGy\|IHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25iYYSgNVAhfU1iYX\0[ZIhPSCqcoOgdJJmfHKnYYTl[EB4cXSqIF3FT\|EhcW6qaXLpeI9zKFCGOUiwOVkh\m:{IEGgbJIh[mWob4LlJINwdXCxdX7kJIFl\Gm2aX;uJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MonFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|NEW2PFUoRjJzM{S1Olg2RC:jPh?=
HeLa	M1u5UmZ2dmO2aX;uJIF{e2G7	MoXMNlAhfU1?	MmTzN{BpenN?		MlruTY5pcWKrdHnvckBw\iCHUluxM\|IheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMkCgeW0h[W[2ZYKgN{BpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?=	NIG5fYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NFYyPSd-MkO1O\|A3OTV:L3G+
RD	NIPKUpVyUFSVIHHzd4F6				NV\ySWl7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NXfLdXAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NXXheHFueUiWUzDhd5NigQ>?				M4jpOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	NX7TVJlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NVLLOlZHeUiWUzDhd5NigQ>?				M3;lfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NES2e3hyUFSVIHHzd4F6				NV\pPYNPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NVn0XWtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MUjxTHRUKGG\|c3H5				M4DXbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NWH3VmJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MDA-MB-231	Mn;pSpVv[3Srb36gZZN{[Xl?	NF7EU5c2OCC3TR?=			NF7q[XZFd3ewcnXneYxifGmxbjDv[kBOVVB{IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	Ml6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mk[yNlYoRjJ{OUK2NlI3RC:jPh?=
MDA-MB-231	MVvGeY5kfGmxbjDhd5NigQ>?	MYS1NEB2VQ>?			MVrEc5dvemWpdXzheIlwdiCxZjDNUXA6KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiNUCgeW0h[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MlryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7Mk[yNlYoRjJ{OUK2NlI3RC:jPh?=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot

c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT ; p-JNK / JNK / Cyclin D1 ; p-HER2 / HER2 ; MMP9 / XIAP / VEGF

17482134 24244023 29695559

In vivo

Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[7]

Protocol (from reference)

Kinase Assay: ^[1]	In vitro MEK-inhibitory activity: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research: ^[1]	Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 3 dyas, or 7-10 days Method: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.
Animal Research: ^[7]	Animal Models: Male Sprague–Dawley rats with acute pancreatitis Dosages: 10 mg/kg Administration: Injection i.v.

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	1mg/mL

Chemical Information

Molecular Weight	267.28
Formula	C₁₆H₁₃NO₃
CAS No.	167869-21-8
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

Download PD98059 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to formulate this inhibitor for i.p. injection?

Answer:
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):